Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the BofA Securities Healthcare Conference in Las Vegas on May 9, 2023, at 5:00 p.m. Pacific Time. The company will engage in a fireside chat, which interested parties can access via a live and archived webcast on their website.

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases such as cancer, autoimmune disorders, and infectious diseases. With a proprietary immune medicine platform, the company aims to develop customized clinical products tailored to individual patients, enhancing the efficiency of disease diagnosis and treatment.

SEATTLE, April 25, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, Nevada.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, May 9^th at 5:00 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
845-344-7542
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

FAQ

What is the date and time of Adaptive Biotechnologies' presentation at the BofA Securities Healthcare Conference?

Adaptive Biotechnologies will present on May 9, 2023, at 5:00 p.m. Pacific Time.

How can I access the webcast of Adaptive Biotechnologies' fireside chat?

The webcast can be accessed live and archived on the Investors section of Adaptive Biotechnologies' website.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating various diseases.

What diseases does Adaptive Biotechnologies aim to diagnose and treat?

The company targets diseases such as cancer, autoimmune disorders, and infectious diseases.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.